Jinwu Financial News | Liankang Biotechnology Group (00690) issued a positive profit forecast. The Group expects to record profit attributable to parent company owners not less than HK$60 million in 2023 (2022: profit of HK$38.51 million).
Based on the information available to the Board of Directors, the Board believes that the expected increase is mainly due to: (1) Sales revenue growth of no less than 10% compared to 2022. Sales revenue for the same period in 2022 was HK$440 million. The increase in revenue was mainly due to the company's continuous academic promotion, further expanding hospital coverage and suitable patient population, and was fully recognized by the market and patients; (2) the Group continued to optimize and control production costs, and continuously deepened cooperation with raw material suppliers to reduce API procurement costs; (3) the Group achieved CMO revenue of more than HK$9 million, an increase of no less than 200% over the same period in 2022.